<DOC>
	<DOC>NCT00978380</DOC>
	<brief_summary>This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the safety of monthly replacement therapy of recombinant factor XIII in patients with congenital FXIII deficiency. The trial continues until the product is commercially available, but an interim assessment will take place when all subjects have completed 52 weeks in the trial.</brief_summary>
	<brief_title>Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor XIII Deficiency</mesh_term>
	<criteria>For subjects who participated in F13CD1725: Previous participation (means up to and inclusive Visit 16, (End of Trial)) in F13CD1725 For all other subjects: Diagnosis of congenital FXIII Asubunit deficiency (confirmed by genotyping at screening visit or documented results from previously performed genotyping) Body weight at least 20 kg Known neutralizing antibodies (inhibitors) towards FXIII Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency Platelet count (thrombocytes) of less than 50 Ã— 109/L. For subjects who participated in F13CD1725 platelet count from visit 15 in F13CD1725 must be used for evaluation. Females of childbearing potential who are pregnant, breastfeeding or are not using adequate contraceptive methods</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>